Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. 2007

Argirios E Tsantes, and Georgios K Nikolopoulos, and Pantelis G Bagos, and Evdoxia Rapti, and Georgios Mantzios, and Violeta Kapsimali, and Anthi Travlou
Laboratory of Hematology & Blood Bank Unit, Attikon General Hospital, School of Medicine, University of Athens, Athens, Greece.

The effect of the 675 insertion/deletion (4G/5G) polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene on the risk of venous thromboembolism (VTE) remains controversial. In this study, we performed a meta-analysis of published data regarding this issue. A comprehensive electronic search was carried out up until September 2006. A total of 22 articles were included in the analysis that was performed using random effects models. Eighteen papers, concerning patients without another known risk factor, comprised 2,644 cases and 3,739 controls. The alleles contrast (4G vs. 5G allele) yielded a statistically significant odds ratio (OR) of 1.153 (95% confidence interval [CI]: 1.068-1.246). In a sub-analysis of five studies that included 256 cases with another genetic risk factor and 147 controls, the combined per-allele OR was still significant (OR: 1.833,95% CI: 1.325-2.536). On the contrary, the analysis of five studies regarding cases with a non-genetic risk factor for VTE (antiphospholipid antibody syndrome, Behcet disease) provided insignificant results in all aspects. There was no evidence for heterogeneity and publication bias in all analyses. Based on our findings, the 4G allele appears to increase the risk of venous thrombosis, particularly in subjects with other genetic thrombophilic defects. Recommendation for detection of this polymorphism in evaluating thrombophilia in such patients might be considered.

UI MeSH Term Description Entries
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D005787 Gene Frequency The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION. Allele Frequency,Genetic Equilibrium,Equilibrium, Genetic,Allele Frequencies,Frequencies, Allele,Frequencies, Gene,Frequency, Allele,Frequency, Gene,Gene Frequencies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D013923 Thromboembolism Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream. Thromboembolisms
D016017 Odds Ratio The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases. Cross-Product Ratio,Risk Ratio,Relative Odds,Cross Product Ratio,Cross-Product Ratios,Odds Ratios,Odds, Relative,Ratio, Cross-Product,Ratio, Risk,Ratios, Cross-Product,Ratios, Risk,Risk Ratios
D017395 Plasminogen Activator Inhibitor 1 A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activators. PAI-1,SERPINE1 Protein,Serpin E1,Type 1 Plasminogen Activator Inhibitor,E1, Serpin,Protein, SERPINE1
D018570 Risk Assessment The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988) Assessment, Risk,Benefit-Risk Assessment,Risk Analysis,Risk-Benefit Assessment,Health Risk Assessment,Risks and Benefits,Analysis, Risk,Assessment, Benefit-Risk,Assessment, Health Risk,Assessment, Risk-Benefit,Benefit Risk Assessment,Benefit-Risk Assessments,Benefits and Risks,Health Risk Assessments,Risk Analyses,Risk Assessment, Health,Risk Assessments,Risk Benefit Assessment,Risk-Benefit Assessments
D020022 Genetic Predisposition to Disease A latent susceptibility to disease at the genetic level, which may be activated under certain conditions. Genetic Predisposition,Genetic Susceptibility,Predisposition, Genetic,Susceptibility, Genetic,Genetic Predispositions,Genetic Susceptibilities,Predispositions, Genetic,Susceptibilities, Genetic
D020246 Venous Thrombosis The formation or presence of a blood clot (THROMBUS) within a vein. Deep Vein Thrombosis,Phlebothrombosis,Thrombosis, Deep Vein,Thrombosis, Venous,Deep Venous Thrombosis,Deep-Vein Thrombosis,Deep-Venous Thrombosis,Deep Vein Thromboses,Deep Venous Thromboses,Deep-Vein Thromboses,Deep-Venous Thromboses,Phlebothromboses,Thromboses, Deep Vein,Thromboses, Deep Venous,Thromboses, Deep-Vein,Thromboses, Deep-Venous,Thromboses, Venous,Thrombosis, Deep Venous,Thrombosis, Deep-Vein,Thrombosis, Deep-Venous,Vein Thromboses, Deep,Vein Thrombosis, Deep,Venous Thromboses,Venous Thromboses, Deep,Venous Thrombosis, Deep

Related Publications

Argirios E Tsantes, and Georgios K Nikolopoulos, and Pantelis G Bagos, and Evdoxia Rapti, and Georgios Mantzios, and Violeta Kapsimali, and Anthi Travlou
December 2014, Thrombosis research,
Argirios E Tsantes, and Georgios K Nikolopoulos, and Pantelis G Bagos, and Evdoxia Rapti, and Georgios Mantzios, and Violeta Kapsimali, and Anthi Travlou
January 2013, PloS one,
Argirios E Tsantes, and Georgios K Nikolopoulos, and Pantelis G Bagos, and Evdoxia Rapti, and Georgios Mantzios, and Violeta Kapsimali, and Anthi Travlou
April 2015, Medical science monitor : international medical journal of experimental and clinical research,
Argirios E Tsantes, and Georgios K Nikolopoulos, and Pantelis G Bagos, and Evdoxia Rapti, and Georgios Mantzios, and Violeta Kapsimali, and Anthi Travlou
February 2015, Journal of receptor and signal transduction research,
Argirios E Tsantes, and Georgios K Nikolopoulos, and Pantelis G Bagos, and Evdoxia Rapti, and Georgios Mantzios, and Violeta Kapsimali, and Anthi Travlou
March 2014, Journal of assisted reproduction and genetics,
Argirios E Tsantes, and Georgios K Nikolopoulos, and Pantelis G Bagos, and Evdoxia Rapti, and Georgios Mantzios, and Violeta Kapsimali, and Anthi Travlou
January 2008, The journal of vascular access,
Argirios E Tsantes, and Georgios K Nikolopoulos, and Pantelis G Bagos, and Evdoxia Rapti, and Georgios Mantzios, and Violeta Kapsimali, and Anthi Travlou
May 2024, Thrombosis journal,
Argirios E Tsantes, and Georgios K Nikolopoulos, and Pantelis G Bagos, and Evdoxia Rapti, and Georgios Mantzios, and Violeta Kapsimali, and Anthi Travlou
January 2012, Rheumatology international,
Argirios E Tsantes, and Georgios K Nikolopoulos, and Pantelis G Bagos, and Evdoxia Rapti, and Georgios Mantzios, and Violeta Kapsimali, and Anthi Travlou
January 2013, BMC medicine,
Argirios E Tsantes, and Georgios K Nikolopoulos, and Pantelis G Bagos, and Evdoxia Rapti, and Georgios Mantzios, and Violeta Kapsimali, and Anthi Travlou
December 2014, The International journal of neuroscience,
Copied contents to your clipboard!